Moreover, the subgroup analyses in the 2 large trials indicated that pCR rate varied from 5% to 50% in different subgroups, suggesting that HR+/HER2– breast cancer possessed a highly heterogeneous tumor immune microenvironment. This evidence concerns the gene ERBB2 and breast cancer.